Universität zu Köln

Ehret, Felix ORCID: 0000-0001-6177-1755, Kaul, David, Kufeld, Markus, Vom Endt, Clara, Budach, Volker ORCID: 0000-0002-2191-9871, Senger, Carolin, Fuerweger, Christoph, Haidenberger, Alfred and Muacevic, Alexander (2023). Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis. J. Cancer Res. Clin. Oncol., 149 (3). S. 1095 - 1102. NEW YORK: SPRINGER. ISSN 1432-1335

Full text not available from this repository.

Abstract

Purpose Adrenal gland metastases (AGMs) are a common manifestation of metastatic tumor spread, especially in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). In patients with a limited systemic tumor burden, effective treatments for AGMs are needed. Due to varying fractionation schemes and limited reports, short-course treatment results for stereotactic body radiotherapy (SBRT) for AGMs are lacking. This work analyzes the outcomes of short-course SBRT for AGMs. Methods Patients who underwent robotic SBRT for AGMs with one to five fractions were eligible for analysis. Results In total, data from 55 patients with 72 AGMs from two institutions were analyzed. Most AGMs originated from renal cell carcinoma (38%) and NSCLC (35%). The median follow-up was 16.4 months. The median prescription dose and isodose line were 24 Gy and 70%, respectively. Most patients (85%) received SBRT with just one fraction. The median biologically effective dose assuming an alpha/beta ratio of 10 (BED10) was 80.4 Gy. The local control and progression-free survival after 1 and 2 years were 92.9%, 67.8%, and 46.2%, as well as 24.3%, respectively. Thirteen patients (24%) suffered from grade 1 or 2 toxicities. The BED10 showed a significant impact on LC (p < 0.01). Treatments with a BED10 equal to or above the median were associated with a better LC (p < 0.01). Conclusion Robotic SBRT is an efficient and safe treatment modality for AGM. Treatment-associated side effects are sporadic and manageable. Results suggest short-course SBRT to be a preferable and time-saving treatment option for the management of AGMs if an adequate BED10 can be safely applied.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Ehret, Felix UNSPECIFIED orcid.org/0000-0001-6177-1755 UNSPECIFIED Kaul, David UNSPECIFIED UNSPECIFIED UNSPECIFIED Kufeld, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED Vom Endt, Clara UNSPECIFIED UNSPECIFIED UNSPECIFIED Budach, Volker UNSPECIFIED orcid.org/0000-0002-2191-9871 UNSPECIFIED Senger, Carolin UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuerweger, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED Haidenberger, Alfred UNSPECIFIED UNSPECIFIED UNSPECIFIED Muacevic, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-686450
DOI:	10.1007/s00432-022-03943-0
Journal or Publication Title:	J. Cancer Res. Clin. Oncol.
Volume:	149
Number:	3
Page Range:	S. 1095 - 1102
Date:	2023
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-1335
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language OLIGOMETASTATIC DISEASE; RADIATION-THERAPY; ONCOLOGY; CANCER; SBRT Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68645